Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients

Cancer Biology and Therapy

Volumn 12, Issue 2, 2011, Pages 112-118

  Correale, Pierpaolo ^a   Botta, Cirino ^a   Basile, Assunta ^a   Pagliuchi, Marco ^a   Licchetta, Antonella ^a   Martellucci, Ignazio ^a   Bestoso, Elena ^a   Apollinari, Serena ^a   Addeo, Raffaele ^b   Misso, Gabriella ^c   Romano, Ornella ^c   Abbruzzese, Alberto ^c   Lamberti, Monica ^d   Luzzi, Luca ^e   Gotti, Giuseppe ^e   Rotundo, Maria Saveria ^d   Caraglia, Michele ^c   Tagliaferri, Pierosandro ^d  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b S Giovanni di Dio Hospital   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^e UNIVERSITY OF SIENA   (Italy)

Author keywords

Bevacizumab; Dose dense metronomic chemotherapy; mPEBev regimen; NSCLC; VEGF

Indexed keywords

BEVACIZUMAB; CISPLATIN; ETOPOSIDE;

ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; COGNITIVE DEFECT; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HEMOPTYSIS; HUMAN; HYPERTENSION; INFECTION; LARGE CELL CARCINOMA; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG CAVITATION; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEINURIA; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING;

EID: 79960388676     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.2.15722     Document Type: Article

References (40)

1. GLOBOCAN 2000. Cancer incidence, mortality and prevalence worldwide. Version IARC CancerBase [N05 Lyon]. IARCPress. Available at: http://www.de.iarc.fr/globocan.htlm.
2. Schrump DS, Altorki NK, Hensechle CL. Cancer of the lung: Non-small cell lung cancer. In: De Vita VTJ, Hellman S, Rosenberg SA, Eds. Cancer Principles and Practice of Oncology. Philadelphia: Lippincott Williams and Wilkins 2005; 7:753-77.
3. Rajeswaran A, Trojan A, Burnand B, Giannelli M. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus nonplatinum-ased doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: A systematic review of randomized controlled trials. Lung Cancer 2008; 59:1-11; PMID: 17720276; DOI:10.1016/j.lungcan.2007.07.012.
4. Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 2004; 292:470-84; PMID: 15280345; DOI: 10.1001/jama.292.4.470.
5. Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, Stahel R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2005; 47:69-80; PMID: 15603856; DOI:10.1016/j.lungcan.2004.10.014.
6. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008; 26:4617-25; PMID: 18678835; DOI: 10.1200/JCO.2008.17.7162.
7. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374:1432-40; PMID: 19767093; DOI:10.1016/S0140- 6736(09)61497-5.
8. Fidias PM, Dakhil SR, Lyss AP, Loesch DM, Waterhouse DM, Bromund JL, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009; 27:591-8; PMID: 19767093; DOI: 10.1200/JCO.2008.17.1405.
9. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11:521-9; PMID: 20493771; DOI:10.1016/S1470-2045(10) 70112-1.
10. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008; 8:579-91; PMID: 18596824; DOI:10.1038/nrc2403.
11. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006; 28:1779-802; PMID: 17212999; DOI: 10.1016/j.clinthera.2006.11.015.
12. Midgley R, Kerr D. Bevacizumab: current status and future directions. Ann Oncol 2005; 16:999-1004; PMID: 15939715; DOI: 10.1093/annonc/mdi208.
13. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-50; PMID: 17167137.
14. Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27:1227-34; PMID: 19188680; DOI: 10.1200/JCO.2007.14.5466.
15. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-mall-cell lung cancer. J Clin Oncol 2004; 22:2184-91; PMID: 15169807; DOI: 10.1200/JCO.2004.11.022.
16. Crinò L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 2010; 11:733-40; PMID: 20650686; DOI: 10.1016/S1470-2045(10)70151-0.
17. Dansin E, Tsai CM, Pavlakis N, Laskin J, Griesinger F, Garrido P, et al. Safety and efficacy of first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC): results of the SAiL study (MO19390). Abstract 168. Proc of ECCO15/ESMO34, 2009.
18. Fischbach NA, Spigel D, Brahmer J, Garst J, Robles R, Chung C, et al. Preliminary safety and effectiveness of bevacizumab (BV) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (NSCLC) from the ARIES study: A bevacizumab (BV) treatment observational cohort study (OCS). J Clin Oncol 2009; 27:15.
19. Miller VA, O'Connor P, Soh C, Kabbinavar F. For the ATLAS investigators. A randomized double blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first line treatment of locally advanced, recurrent or metastatic non-small cell lung cancer (NCSLC). J Clin Oncol 2009; 27:18.
20. Correale P, Remondo C, Carbone SF, Ricci V, Migali C, Martellucci I, et al. Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients. Cancer Biol Ther 2010; 9:685-93; PMID: 20697196; DOI: 10.4161/ cbt.9.9.11441.
21. Scharovsky OD, Mainetti LE, Rozados VR. Metronomic chemotherapy: changing the paradigm that more is better. Curr Oncol 2009; 16:7-15; PMID: 19370174.
22. Shaked Y, Emmenegger U, Man S, Cervi D, Bertolini F, Ben-David Y, et al. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 2005; 106:3058-61; PMID: 15998832; DOI: 10.1182/blood-2005-04-1422.
23. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4:423-36; PMID: 15170445; DOI:10.1038/nrc1369.
24. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56:641-8; PMID: 16960692; DOI: 10.1007/s00262-006-0225-8.
25. Laquente B, Viñals F, Germà JR. Metronomic chemotherapy: an antiangiogenic scheduling. Clin Transl Oncol 2007; 9:93-8; PMID: 17329220.
26. Zagozdzon R, Golab J. Immunomodulation by anticancer chemotherapy: more is not always better (review). Int J Oncol 2001; 18:417-24; PMID: 11172612.
27. Correale P, Cerretani D, Remondo C, Martellucci I, Marsili S, La Placa M, et al. A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients. Oncol Rep 2006; 16:133-40; PMID: 16786136.
28. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67:361-70; PMID: 6880820.
29. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: Bevacizumab (avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 2007; 12:713-8; PMID: 17602060; DOI:10.1634/theoncologist.12-6-713.
30. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-76; PMID: 18160686.
31. Meyer T, Robles-Carrillo L, Robson T, Langer F, Desai H, Davila M, et al. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost 2009; 7:171-81; PMID: 18983497; DOI: 10.1111/j.1538-7836.2008.03212.x.
32. Werther K, Christensen IJ, Nielsen H. Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets. Scand J Clin Lab Invest 2002; 62:343-50; PMID: 12387579.
33. Salven P, Orpana A, Joensuu H. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 1999; 5:487-91; PMID: 10100697.
34. Elfving B, Plougmann PH, Wegener G. Differential brain, but not serum VEGF levels in a genetic rat model of depression. Neurosci Lett 2010; 474:13-6; PMID: 20193739; DOI: 10.1016/j.neulet.2010.02.063.
35. Greene J, Banasr M, Lee B, Warner-Schmidt J, Duman RS. Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterization. Neuropsychopharmacology 2009; 34:2459-68; PMID: 19553916.
36. Warner-Schmidt JL, Duman RS. VEGF as a potential target for therapeutic intervention in depression. Curr Opin Pharmacol 2008; 8:14-9; PMID: 18061540; DOI: 10.1016/j.coph.2007.10.013.
37. Warner-Schmidt JL, Duman RS. VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci USA 2007; 104:4647-52; PMID: 17360578; DOI: 10.1073/pnas.0610282104.
38. Dietrich J, Monje M, Wefel J, Meyers C. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist 2008; 13:1285-95; PMID: 19019972; DOI: 10.1634/theoncologist. 2008-0130.
39. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26:3543-51; PMID: 18506025; DOI: 10.1200/JCO.2007.15.0375.
40. Klebanoff SJ, Waltersdorph AM, Rosen H. Antimicrobial activity of myeloperoxidase. Methods Enzymol 1984; 105:399-403; PMID: 6328193.